PMID- 10934080
OWN - NLM
STAT- MEDLINE
DCOM- 20000915
LR  - 20181025
IS  - 1073-449X (Print)
IS  - 1073-449X (Linking)
VI  - 162
IP  - 2 Pt 1
DP  - 2000 Aug
TI  - Long-term follow-up of hexamethylene diisocyanate-, diphenylmethane 
      diisocyanate-, and toluene diisocyanate-induced asthma.
PG  - 516-22
AB  - In 1976-1992 245 new cases of asthma induced by diisocyanates were diagnosed, 
      caused by hexamethylene diisocyanate (HDI) in 39%, diphenylmethane diisocyanate 
      (MDI) in 39%, and toluene diisocyanate (TDI) in 17% of the cases. Our aim was to 
      study the clinical outcome of diisocyanate-induced asthma. A questionnaire was 
      sent to the 235 patients alive in 1995, and validated by reexamining clinically 
      91 of them. The study was carried out on average 10 () yr after the diagnosis. Of 
      the patients 82% experienced symptoms of asthma, 34% used no medication, and 35% 
      were on regular medication. The patients having displayed immunoglobulin E (IgE) 
      antibodies to isocyanates used less medication (OR 0.273; CI 0.098, 0.758) and 
      had fewer symptoms of asthma (OR 0.329; CI 0.124, 0.875) than the IgE-negative 
      ones. They also had a significantly shorter duration of symptoms (p = 0.0025), 
      latency period (p = 0.0249), and duration of exposure (p = 0.0008) than the 
      IgE-negative patients. This did not, however, entirely explain the more 
      favourable outcome of the IgE-positive patients. Patients with HDI-induced asthma 
      used less medication (OR 0.412; CI 0.229, 0.739) than patients with MDI- and 
      TDI-induced asthma. The results confirm the generally rather poor medical outcome 
      of diisocyanate-induced asthma; the persistence of symptoms and unspecific 
      bronchial reactivity were pronounced in TDI-induced asthma. A more favourable 
      outcome was associated with IgE mediation and HDI inducement.
FAU - Piirila, P L
AU  - Piirila PL
AD  - Finnish Institute of Occupational Health and Helsinki University Hospital, 
      Helsinki, Finland. Paivi.Piirila@occuphealth.fi
FAU - Nordman, H
AU  - Nordman H
FAU - Keskinen, H M
AU  - Keskinen HM
FAU - Luukkonen, R
AU  - Luukkonen R
FAU - Salo, S P
AU  - Salo SP
FAU - Tuomi, T O
AU  - Tuomi TO
FAU - Tuppurainen, M
AU  - Tuppurainen M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Respir Crit Care Med
JT  - American journal of respiratory and critical care medicine
JID - 9421642
RN  - 0 (Air Pollutants)
RN  - 0 (Allergens)
RN  - 0 (Cyanates)
RN  - 0 (Isocyanates)
RN  - 0I70A3I1UF (1,6-hexamethylene diisocyanate)
RN  - 17X7AFZ1GH (Toluene 2,4-Diisocyanate)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - B0LO6BBS8C (4,4'-diphenylmethane diisocyanate)
SB  - IM
MH  - Adult
MH  - Air Pollutants/*adverse effects
MH  - Allergens/*adverse effects
MH  - Asthma/*chemically induced/drug therapy/immunology
MH  - Cyanates/*adverse effects
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Isocyanates/*adverse effects
MH  - Male
MH  - Surveys and Questionnaires
MH  - Toluene 2,4-Diisocyanate/*adverse effects
EDAT- 2000/08/10 11:00
MHDA- 2000/09/23 11:01
CRDT- 2000/08/10 11:00
PHST- 2000/08/10 11:00 [pubmed]
PHST- 2000/09/23 11:01 [medline]
PHST- 2000/08/10 11:00 [entrez]
AID - 10.1164/ajrccm.162.2.9909026 [doi]
PST - ppublish
SO  - Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):516-22. doi: 
      10.1164/ajrccm.162.2.9909026.